Log in
Enquire now
Kyverna Therapeutics

Kyverna Therapeutics

Kyverna is a cell therapy company engineering a new class of curative living medicines for inflammatory and autoimmune diseases.

OverviewStructured DataIssuesContributors

Contents

kyvernatx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Regenerative medicine
Regenerative medicine
Autoimmune disease
Autoimmune disease
Biomedical engineering
Biomedical engineering
Healthcare
Healthcare
Biotechnology
Biotechnology
Genomics
Genomics
‌
Genome editing
Cell therapy
Cell therapy
...
Location
Emeryville, California
Emeryville, California
San Francisco
San Francisco
CEO
Dominic Borie
Dominic Borie
0
Founder
Jeffrey Greve
Jeffrey Greve
Pitchbook URL
pitchbook.com/profiles...331311-16
Date Incorporated
2018
Number of Employees (Ranges)
51 – 2000
Email Address
partners@kyvernatx.com0
hello@kyvernatx.com0
media@kyvernatx.com0
Full Address
5980 Horton St, Suite 550, Emeryville, California 94608, US0
Investors
Vida Ventures
Vida Ventures
Gilead Sciences
Gilead Sciences
Insight Partners
Insight Partners
Intellia Therapeutics
Intellia Therapeutics
jVen Capital
jVen Capital
Westlake Village BioPartners
Westlake Village BioPartners
Northpond Ventures
Northpond Ventures
...
Founded Date
2018
Total Funding Amount (USD)
110,000,000
Latest Funding Round Date
January 26, 2022
Glassdoor ID
https://www.glassdoor.com/Overview/Working-at-Kyverna-Therapeutics-EI_IE6483224.11,31.htm0
Key People
Julie Winter
Julie Winter
0
Ryan Jones
Ryan Jones
0
Gregory J. Giotta
Gregory J. Giotta
0
Dominic Borie
Dominic Borie
0
James Chung
James Chung
0
Tom Van Blarcom
Tom Van Blarcom
0
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Technologies Used
CRISPR
CRISPR
Country
United States
United States

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
85,000,000
Public/Private
Private0

Kyverna Therapeutics is a cell therapy company developing therapies for autoimmune diseases. The company applies T cell engineering and synthetic biology technologies to develop therapies that aim to suppress and eliminate the autoreactive immune cells at the root of inflammatory diseases. Kyverna is collaborating with Gilead Sciences and received Series A investment from Vida Ventures, Westlake Village BioPartners and Gilead Sciences. Kyverna’s collaboration and licensing agreement with Gilead is for the development of engineered T cell therapies for treatment of autoimmune disease using Kyverna’s synthetic Treg platform and the synNotch technology from the Gilead company, Kite Pharma.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Kyverna Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.